Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
-
Biomed Testing Facility # BIO-01-85012, Phoenix, Arizona, United States, 85012
Biomed Testing Facility # BIO-05-92093, La Jolla, California, United States, 92093
Biomed Testing Facility # BIO-04-90095, Los Angeles, California, United States, 90045
Biomed Testing Facility # BIO-03-95817, Sacramento, California, United States, 95817
Biomed Testing Facility # BIO-02-94104, San Francisco, California, United States, 94104
Biomed Testing Facility #BIO-06-80042, Aurora, Colorado, United States, 80042
Biomed Testing Facility #BIO-07-33606, Tampa, Florida, United States, 33606
Biomed Testing Facility #BIO-08-60612, Chicago, Illinois, United States, 60612
Maryland Locations Biomed Testing Facility #BIO-9-21205, Baltimore, Maryland, United States, 21205
Biomed Testing Facility #BIO-10-02115, Boston, Massachusetts, United States, 02115
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
5 Years to 20 Years
FEMALE
No
Biomed Industries, Inc.,
Lloyd L Tran, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
David Nguyen, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
Zung V Tran, PhD, STUDY_DIRECTOR, Biomed Industries, Inc.
2026-03-15